Mirum Pharmaceuticals Stock Price, News & Analysis

Mirum Pharmaceuticals (NASDAQ: MIRM) has appointed Doug Sheehy, JD as Chief Legal Officer. Sheehy brings nearly 20 years of experience in leading global legal and compliance operations for biopharmaceutical companies. His most recent role was CLO at Sonoma Biotherapeutics. Previously, he served as general counsel at Aimmune Therapeutics (2016-2020) until its Nestle Health Science acquisition, and as EVP, CAO, and general counsel at Codexis (2007-2016). Sheehy holds an A.B. in History from Dartmouth College and a J.D. from American University. CEO Chris Peetz highlighted that Sheehy's extensive global legal experience will strengthen Mirum's capabilities as they expand their commercial business and advance their rare disease pipeline.

Mirum Pharmaceuticals (Nasdaq: MIRM), a biopharmaceutical company specializing in rare and orphan diseases, has announced its participation in two upcoming investor conferences in May 2025. The company will attend the 3rd Annual H.C. Wainwright BioConnect Investor Conference on May 20th and deliver a company presentation at the RBC Capital Markets Global Healthcare Conference on May 21st at 9:00 AM ET. Interested parties can access webcast links and additional information through the Investors and Media section of Mirum's corporate website.

Mirum Pharmaceuticals (NASDAQ: MIRM) announced inducement awards granted to eight new employees on May 9, 2025. The awards, approved by the Compensation Committee, include:

- Stock options to purchase 53,230 shares at $44.27 per share (closing price on May 9), vesting over 4 years with 25% vesting after one year and remaining monthly over 36 months

- 26,585 restricted stock units (RSUs) vesting over 3 years with 33% vesting annually

The grants were made under Mirum's 2020 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), subject to continued employment.

Mirum Pharmaceuticals presented promising 28-week data from its Phase 2b VANTAGE study evaluating volixibat for cholestatic pruritus in primary biliary cholangitis (PBC) patients at EASL. The study showed statistically significant improvements in pruritus (itching) and numeric improvements in fatigue, the two most burdensome PBC symptoms.

Key findings include:

• 70% of volixibat-treated patients achieved ≥50% reduction in serum bile acids
• Statistically significant 3.78-point reduction in ItchRO from baseline in the combined dose group
• Both 20mg and 80mg BID doses showed similar efficacy
• Improvements in quality of life measures and reductions in IL-31 inflammatory biomarker

The most common adverse event was mild to moderate diarrhea (77%). Based on similar efficacy and safety results, the 20mg BID dose was selected for the confirmatory portion of the VANTAGE study.

Mirum Pharmaceuticals (MIRM) reported strong Q1 2025 financial results with total revenue of $111.6 million, a significant increase from $69.2 million in Q1 2024. The company raised its 2025 revenue guidance to $435-450 million. LIVMARLI net product sales reached $73.2 million (71% YoY growth), while Bile Acid Medicines contributed $38.4 million (47% YoY growth). Key achievements include FDA approval of LIVMARLI's oral tablet formulation, Japanese approval for ALGS and PFIC, and CTEXLI approval in the US. The VISTAS study for volixibat in PSC is expected to complete enrollment in Q3 2025. Mirum maintains a strong financial position with $298.6 million in cash and investments as of March 31, 2025.

Mirum Pharmaceuticals (NASDAQ: MIRM) has scheduled its first quarter 2025 financial results announcement for Wednesday, May 7, 2025. The company will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss both the financial performance and recent corporate developments.

Investors and interested parties can access the call through multiple channels:

• U.S./Toll-Free: +1 833 470 1428
• International: +1 404 975 4839
• Passcode: 549600

Additionally, a webcast will be available through the Events & Presentations section on Mirum's website. For those unable to attend live, a replay of the webcast will remain accessible for 30 days following the call.

Mirum Pharmaceuticals (NASDAQ: MIRM) has announced upcoming data presentations at three major medical congresses in May 2025: Digestive Disease Week (DDW) in San Diego, European Association for the Study of the Liver (EASL) in Amsterdam, and ESPGHAN in Helsinki.

A key highlight includes new 28-week data from the Phase 2b VANTAGE study of volixibat in PBC patients, showing significant improvements in cholestatic pruritus. The study demonstrated that 70% of volixibat-treated patients achieved ≥50% reduction in serum bile acid levels, with improvements in fatigue and sleep. The most common side effect was mild to moderate diarrhea.

The presentations will feature data from LIVMARLI and volixibat studies across multiple sessions, including oral presentations, posters, and symposiums focusing on cholestatic liver diseases, PFIC, and Alagille syndrome treatment outcomes.

Mirum Pharmaceuticals (NASDAQ: MIRM) has received FDA approval for a new tablet formulation of LIVMARLI® (maralixibat) for treating cholestatic pruritus in patients with Alagille syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC).

The tablet version will complement the existing liquid formulation, offering greater flexibility in treatment options. While younger patients can continue using the liquid form, older patients will benefit from a convenient one-tablet per dose option. The company plans to make LIVMARLI tablets available in June through Mirum Access Plus.

Mirum Pharmaceuticals (MIRM) has announced inducement awards for seven new employees under its 2020 Inducement Plan. The awards, approved by the Compensation Committee, include:

• 39,740 non-qualified stock options with an exercise price of $39.12 per share (closing price on April 10, 2025)
• 19,830 restricted stock units (RSUs)

The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over three years, with 33% vesting annually. Both awards are contingent on continued employment with Mirum through vesting dates.